Original Research
Published on 12 Sep 2022
Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
in Drugs Outcomes Research and Policies
- 3,124 views
- 9 citations
Original Research
Published on 12 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 12 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 08 Sep 2022
in Drugs Outcomes Research and Policies
Systematic Review
Published on 08 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 07 Sep 2022
in Drugs Outcomes Research and Policies
Clinical Trial
Published on 07 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 06 Sep 2022
in Drugs Outcomes Research and Policies
Systematic Review
Published on 06 Sep 2022
in Drugs Outcomes Research and Policies
Correction
Published on 06 Sep 2022
in Drugs Outcomes Research and Policies
Policy and Practice Reviews
Published on 06 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 06 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 06 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 06 Sep 2022
in Drugs Outcomes Research and Policies
Review
Published on 05 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 02 Sep 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 02 Sep 2022
in Drugs Outcomes Research and Policies